Skip to main content

Table 2 The change of CKD stages compared with baseline at year 3 and year 4 with LdT or ETV

From: Comparison of telbivudine and entecavir on the change of off- treatment eGFR after 3 years of treatment in non-cirrhotic chronic hepatitis B patients

 

LdT (n = 46)

ETV (n = 46)

P-value

Year 3 compared with baseline

 CKD stages (%)

  

0.004

  CKD improved

11 (24.0)

1 (2.2)

  CKD no changed

32 (69.6)

37 (80.4)

  CKD worsen

3 (6.5)

8 (17.4)

Year 4 compared with baseline

 CKD stages (%)

  

0.07

  CKD improved

11 (23.9)

5 (10.9)

  CKD no changed

32 (69.6)

32 (69.6)

  CKD worsen

3 (6.5)

9 (19.6)

  1. The CKD status was analyzed with χ2 test